197 related articles for article (PubMed ID: 33631934)
1. Discovery of TAK-981, a First-in-Class Inhibitor of SUMO-Activating Enzyme for the Treatment of Cancer.
Langston SP; Grossman S; England D; Afroze R; Bence N; Bowman D; Bump N; Chau R; Chuang BC; Claiborne C; Cohen L; Connolly K; Duffey M; Durvasula N; Freeze S; Gallery M; Galvin K; Gaulin J; Gershman R; Greenspan P; Grieves J; Guo J; Gulavita N; Hailu S; He X; Hoar K; Hu Y; Hu Z; Ito M; Kim MS; Lane SW; Lok D; Lublinsky A; Mallender W; McIntyre C; Minissale J; Mizutani H; Mizutani M; Molchinova N; Ono K; Patil A; Qian M; Riceberg J; Shindi V; Sintchak MD; Song K; Soucy T; Wang Y; Xu H; Yang X; Zawadzka A; Zhang J; Pulukuri SM
J Med Chem; 2021 Mar; 64(5):2501-2520. PubMed ID: 33631934
[TBL] [Abstract][Full Text] [Related]
2. Allosteric Inhibition of Ubiquitin-like Modifications by a Class of Inhibitor of SUMO-Activating Enzyme.
Li YJ; Du L; Wang J; Vega R; Lee TD; Miao Y; Aldana-Masangkay G; Samuels ER; Li B; Ouyang SX; Colayco SA; Bobkova EV; Divlianska DB; Sergienko E; Chung TDY; Fakih M; Chen Y
Cell Chem Biol; 2019 Feb; 26(2):278-288.e6. PubMed ID: 30581133
[TBL] [Abstract][Full Text] [Related]
3. SUMO-mimicking peptides inhibiting protein SUMOylation.
Zhao B; Villhauer EB; Bhuripanyo K; Kiyokawa H; Schindelin H; Yin J
Chembiochem; 2014 Dec; 15(18):2662-6. PubMed ID: 25412743
[TBL] [Abstract][Full Text] [Related]
4. T Cell-intrinsic Immunomodulatory Effects of TAK-981 (Subasumstat), a SUMO-activating Enzyme Inhibitor, in Chronic Lymphocytic Leukemia.
Lam V; Roleder C; Liu T; Bruss N; Best S; Wang X; Phillips T; Shouse G; Berger AJ; Alinari L; Wang L; Siddiqi T; Pennock ND; Danilov AV
Mol Cancer Ther; 2023 Sep; 22(9):1040-1051. PubMed ID: 37420267
[TBL] [Abstract][Full Text] [Related]
5. Targeting SUMO Signaling to Wrestle Cancer.
Kroonen JS; Vertegaal ACO
Trends Cancer; 2021 Jun; 7(6):496-510. PubMed ID: 33353838
[TBL] [Abstract][Full Text] [Related]
6. Identification of quinazolinyloxy biaryl urea as a new class of SUMO activating enzyme 1 inhibitors.
Kumar A; Ito A; Hirohama M; Yoshida M; Zhang KY
Bioorg Med Chem Lett; 2013 Sep; 23(18):5145-9. PubMed ID: 23920437
[TBL] [Abstract][Full Text] [Related]
7. Probing the roles of SUMOylation in cancer cell biology by using a selective SAE inhibitor.
He X; Riceberg J; Soucy T; Koenig E; Minissale J; Gallery M; Bernard H; Yang X; Liao H; Rabino C; Shah P; Xega K; Yan ZH; Sintchak M; Bradley J; Xu H; Duffey M; England D; Mizutani H; Hu Z; Guo J; Chau R; Dick LR; Brownell JE; Newcomb J; Langston S; Lightcap ES; Bence N; Pulukuri SM
Nat Chem Biol; 2017 Nov; 13(11):1164-1171. PubMed ID: 28892090
[TBL] [Abstract][Full Text] [Related]
8. Identification of sumoylation activating enzyme 1 inhibitors by structure-based virtual screening.
Kumar A; Ito A; Hirohama M; Yoshida M; Zhang KY
J Chem Inf Model; 2013 Apr; 53(4):809-20. PubMed ID: 23544417
[TBL] [Abstract][Full Text] [Related]
9. Targeting pancreatic cancer by TAK-981: a SUMOylation inhibitor that activates the immune system and blocks cancer cell cycle progression in a preclinical model.
Kumar S; Schoonderwoerd MJA; Kroonen JS; de Graaf IJ; Sluijter M; Ruano D; González-Prieto R; Verlaan-de Vries M; Rip J; Arens R; de Miranda NFCC; Hawinkels LJAC; van Hall T; Vertegaal ACO
Gut; 2022 Nov; 71(11):2266-2283. PubMed ID: 35074907
[TBL] [Abstract][Full Text] [Related]
10. A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment.
Hyer ML; Milhollen MA; Ciavarri J; Fleming P; Traore T; Sappal D; Huck J; Shi J; Gavin J; Brownell J; Yang Y; Stringer B; Griffin R; Bruzzese F; Soucy T; Duffy J; Rabino C; Riceberg J; Hoar K; Lublinsky A; Menon S; Sintchak M; Bump N; Pulukuri SM; Langston S; Tirrell S; Kuranda M; Veiby P; Newcomb J; Li P; Wu JT; Powe J; Dick LR; Greenspan P; Galvin K; Manfredi M; Claiborne C; Amidon BS; Bence NF
Nat Med; 2018 Feb; 24(2):186-193. PubMed ID: 29334375
[TBL] [Abstract][Full Text] [Related]
11. SUMO, Ubiquitin, UBL Proteins: Implications For Human Diseases - Fifth International Conference.
Skaug B; Chen ZJ
IDrugs; 2010 Apr; 13(4):224-7. PubMed ID: 20373248
[TBL] [Abstract][Full Text] [Related]
12. Mechanistic studies of substrate-assisted inhibition of ubiquitin-activating enzyme by adenosine sulfamate analogues.
Chen JJ; Tsu CA; Gavin JM; Milhollen MA; Bruzzese FJ; Mallender WD; Sintchak MD; Bump NJ; Yang X; Ma J; Loke HK; Xu Q; Li P; Bence NF; Brownell JE; Dick LR
J Biol Chem; 2011 Nov; 286(47):40867-77. PubMed ID: 21969368
[TBL] [Abstract][Full Text] [Related]
13. Regulation of cancer-related pathways by protein NEDDylation and strategies for the use of NEDD8 inhibitors in the clinic.
Abidi N; Xirodimas DP
Endocr Relat Cancer; 2015 Feb; 22(1):T55-70. PubMed ID: 25504797
[TBL] [Abstract][Full Text] [Related]
14. Domain alternation and active site remodeling are conserved structural features of ubiquitin E1.
Lv Z; Yuan L; Atkison JH; Aldana-Masangkay G; Chen Y; Olsen SK
J Biol Chem; 2017 Jul; 292(29):12089-12099. PubMed ID: 28572513
[TBL] [Abstract][Full Text] [Related]
15. Biochemical characterization of SUMO-conjugating enzymes by in vitro sumoylation assays.
Eisenhardt N; Ilic D; Nagamalleswari E; Pichler A
Methods Enzymol; 2019; 618():167-185. PubMed ID: 30850051
[TBL] [Abstract][Full Text] [Related]
16. SUMOylation inhibition overcomes proteasome inhibitor resistance in multiple myeloma.
Heynen GJJE; Baumgartner F; Heider M; Patra U; Holz M; Braune J; Kaiser M; Schäffer I; Bamopoulos SA; Ramberger E; Murgai A; Ng YLD; Demel UM; Laue D; Liebig S; Krüger J; Janz M; Nogai A; Schick M; Mertins P; Müller S; Bassermann F; Krönke J; Keller U; Wirth M
Blood Adv; 2023 Feb; 7(4):469-481. PubMed ID: 35917568
[TBL] [Abstract][Full Text] [Related]
17. SUMO pathway inhibition targets an aggressive pancreatic cancer subtype.
Biederstädt A; Hassan Z; Schneeweis C; Schick M; Schneider L; Muckenhuber A; Hong Y; Siegers G; Nilsson L; Wirth M; Dantes Z; Steiger K; Schunck K; Langston S; Lenhof HP; Coluccio A; Orben F; Slawska J; Scherger A; Saur D; Müller S; Rad R; Weichert W; Nilsson J; Reichert M; Schneider G; Keller U
Gut; 2020 Aug; 69(8):1472-1482. PubMed ID: 32001555
[TBL] [Abstract][Full Text] [Related]
18. Structure-Based Design and Identification of FT-2102 (Olutasidenib), a Potent Mutant-Selective IDH1 Inhibitor.
Caravella JA; Lin J; Diebold RB; Campbell AM; Ericsson A; Gustafson G; Wang Z; Castro J; Clarke A; Gotur D; Josephine HR; Katz M; Kershaw M; Yao L; Toms AV; Barr KJ; Dinsmore CJ; Walker D; Ashwell S; Lu W
J Med Chem; 2020 Feb; 63(4):1612-1623. PubMed ID: 31971798
[TBL] [Abstract][Full Text] [Related]
19. SUMO proteases as potential targets for cancer therapy.
Bialik P; Woźniak K
Postepy Hig Med Dosw (Online); 2017 Dec; 71(0):997-1004. PubMed ID: 29225200
[TBL] [Abstract][Full Text] [Related]
20. SUMO pathway components as possible cancer biomarkers.
Mattoscio D; Chiocca S
Future Oncol; 2015; 11(11):1599-610. PubMed ID: 26043214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
